Gilead sciences, inc. GILD.US Overview Analysis
GILD AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock excels in value rating and ranks among the top in dividend scores. It's a prime choice for long-term accumulation. For optimal entry, check our trend and swing trading ratings.
GILD Current Performance
0.42%
Gilead sciences, inc.
3.56%
Avg of Sector
1.47%
S&P500
Top 10 High Relevance to GILD
- JNJ Johnson & johnsonValue 2Trend 2Swing Trading 4Whale Interest 4Dividend 5See more
GILD Profile
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.